SCHEMBL10207136

SCHEMBL10207136

CCOC(=O)C(CO)(CCCCB1OC(C)(C)C(C)(C)O1)NC(C)=O

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.45
THRB P10828 1/20 0.45
HTT P42858 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ATM Q13315 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
APP P05067 2/20 0.32
ALDH1A1 P00352 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19764739 0.92 PKM (0.46) PKMTHRBHTTKDM4EATM
SCHEMBL10207142 0.88 PKM (0.43) PKMTHRBHTTKDM4EATM
Hydrochloric Acid SCHEMBL17896124 0.88 PKM (0.43) PKMTHRBHTTKDM4EATM
SCHEMBL10207154 0.87 PKM (0.42) PKMTHRBHTTKDM4EATM
SCHEMBL894997 0.86 PKM (0.36) PKMTHRBHTTKDM4EATM
SCHEMBL10207153 0.86 PKM (0.41) PKMTHRBHTTKDM4EATM
SCHEMBL16309673 0.85 MEN1 (0.35) PKMTHRBHTTKDM4EATM
SCHEMBL10207155 0.83 PKM (0.38) PKMTHRBHTTKDM4EATM
SCHEMBL894621 0.81 MEN1 (0.39) HTTATMMEN1KMT2AALDH1A1
SCHEMBL10207137 0.80 PKM (0.44) PKMTHRBHTTKDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994594-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2018-06-12 US disclosed
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2017-06-29 US disclosed
US-9040703-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2015-05-26 US disclosed
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-12-18 US disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 PKM 909/4885THRB 2176/4885HTT 4239/4885
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 PKM 909/4885THRB 2176/4885HTT 4239/4885
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 PKM 909/4885THRB 2176/4885HTT 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.